KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Gross Margin (2016 - 2025)

Historic Gross Margin for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Q3 2025 value amounting to 90.13%.

  • Supernus Pharmaceuticals' Gross Margin rose 1400.0% to 90.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 88.61%, marking a year-over-year decrease of 4400.0%. This contributed to the annual value of 88.23% for FY2024, which is 20200.0% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Gross Margin of 90.13% as of Q3 2025, which was up 1400.0% from 89.83% recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Gross Margin ranged from a high of 90.13% in Q3 2025 and a low of 82.29% during Q2 2021
  • Moreover, its 5-year median value for Gross Margin was 88.06% (2023), whereas its average is 87.52%.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Gross Margin crashed by -110900bps in 2021 and then skyrocketed by 56800bps in 2022.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Gross Margin stood at 89.32% in 2021, then decreased by -3bps to 86.28% in 2022, then grew by 2bps to 88.06% in 2023, then decreased by -3bps to 85.01% in 2024, then increased by 6bps to 90.13% in 2025.
  • Its Gross Margin stands at 90.13% for Q3 2025, versus 89.83% for Q2 2025 and 89.48% for Q1 2025.